VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN. - Nester, Carla M.; Bomback, Andrew S.; Ariceta, Gema; Delmas, Yahsou; Dixon, Bradley P.; Gale, Daniel P.; Greenbaum, Larry A.; Han, Seung Hyeok; Isbel, Nicole; Licht, Christoph; Mastrangelo, Antonio; Mizuno, Masashi; et al. (Immunobiology, 2025)